composite; macrolide; readmission; time to event; treatment failure
Abstract :
[en] Rationale: Azithromycin prevents acute exacerbations of chronic obstructive pulmonary disease (AECOPDs); however, its value in the treatment of an AECOPD requiring hospitalization remains to be defined.Objectives: We investigated whether a 3-month intervention with low-dose azithromycin could decrease treatment failure (TF) when initiated at hospital admission and added to standard care.Methods: In an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial, patients who had been hospitalized for an AECOPD and had a smoking history of >/=10 pack-years and one or more exacerbations in the previous year were randomized (1:1) within 48 hours of hospital admission to azithromycin or placebo. The study drug (500 mg/d for 3 d) was administered on top of a standardized acute treatment of systemic corticosteroids and antibiotics, and subsequently continued for 3 months (250 mg/2 d). The patients were followed for 6 months thereafter. Time-to-first-event analyses evaluated the TF rate within 3 months as a novel primary endpoint in the intention-to-treat population, with TF defined as the composite of treatment intensification with systemic corticosteroids and/or antibiotics, a step-up in hospital care or readmission for respiratory reasons, or all-cause mortality.Measurements and Main Results: A total of 301 patients were randomized to azithromycin (n = 147) or placebo (n = 154). The TF rate within 3 months was 49% in the azithromycin group and 60% in the placebo group (hazard ratio, 0.73; 95% confidence interval, 0.53-1.01; P = 0.0526). Treatment intensification, step-up in hospital care, and mortality rates within 3 months were 47% versus 60% (P = 0.0272), 13% versus 28% (P = 0.0024), and 2% versus 4% (P = 0.5075) in the azithromycin and placebo groups, respectively. Clinical benefits were lost 6 months after withdrawal.Conclusions: Three months of azithromycin for an infectious AECOPD requiring hospitalization may significantly reduce TF during the highest-risk period. Prolonged treatment seems to be necessary to maintain clinical benefits.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Vermeersch, Kristina
Gabrovska, Maria
Aumann, Joseph
Demedts, Ingel K.
Corhay, Jean-Louis ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, Castro-Acosta A, Studnicka M, Kaiser B, et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD audit. Eur Respir J 2016;47:113-121.
Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP, Vestbo J, Feenstra TL. Case fatality of COPD exacerbations: A metaanalysis and statistical modelling approach. Eur Respir J 2011; 37:508-515.
Lodewijckx C, Sermeus W, Vanhaecht K, Panella M, Deneckere S, Leigheb F, et al. Inhospital management of COPD exacerbations: A systematic review of the literature with regard to adherence to international guidelines. J Eval Clin Pract 2009;15:1101-1110.
Chow L, Parulekar AD, Hanania NA. Hospital management of acute exacerbations of chronic obstructive pulmonary disease. J Hosp Med 2015;10:328-339.
Soo Hoo GW, Esquinas AM. Risk trajectories of readmission and death in the first year after hospitalization for chronic obstructive pulmonary disease: Don't shortchange noninvasive ventilation. Am J Respir Crit Care Med 2018;198:282-283.
Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD, 2018 report [Internet]; 2018 [accessed 2018 Sept 30]. Available from: Http://goldcopd.org.
Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al.; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365: 689-698.
Ni W, Shao X, Cai X, Wei C, Cui J, Wang R, et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: A meta-analysis. PLoS One 2015;10: E0121257.
Uzun S, Djamin RS, Kluytmans JAJW, Mulder PG, van't Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): A randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2014;2:361-368.
Li H, Liu DH, Chen LL, Zhao Q, Yu YZ, Ding JJ, et al. Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. Antimicrob Agents Chemother 2014;58: 511-517.
Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 2013;1:262-274.
FDA Drug Safety Communication: Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms (safety announcement 3-12-2013). U.S. Food and Drug Aministration [Internet] [accessed 2018 Sept 30]. Available from: Https://www.fda.gov/downloads/ Drugs/DrugSafety/UCM343347.pdf.
Wallace MR, Miller LK, Nguyen MT, Shields AR. Ototoxicity with azithromycin. Lancet 1994;343:241.
Vermeersch K, Gabrovska M, Aumann J, Demedts IK, Corhay J-L, Marchand E, et al. Late breaking abstract - azithromycin for acute COPD exacerbations requiring hospitalization - the BACE trial results. Eur Resp J 2018;52(Suppl 62):OA1654.
Vermeersch K, Gabrovska M, Deslypere G, Demedts IK, Slabbynck H, Aumann J, et al. The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: An investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis 2016;11: 687-696.
Vandenberk B, Vandael E, Robyns T, Vandenberghe J, Garweg C, Foulon V, et al. Which QT correction formulae to use for QT monitoring?. J Am Heart Assoc 2016;5:1-10.
Demeester K, Topsakal V, Hendrickx JJ, Fransen E, van Laer L, Van Camp G, et al. Hearing disability measured by the speech, spatial, and qualities of hearing scale in clinically normal-hearing and hearing-impaired middle-aged persons, and disability screening by means of a reduced SSQ (the SSQ5). Ear Hear 2012; 33:615-616.
Seemungal TAR, Wilkinson TMA, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178:1139-1147.
Khakban A, Sin DD, FitzGerald JM, McManus BM, Ng R, Hollander Z, et al. The projected epidemic of chronic obstructive pulmonary disease hospitalizations over the next 15 years: A populationbased perspective. Am J Respir Crit Care Med 2017;195: 287-291.
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al.; IMPACT Investigators. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018;378: 1671-1680.
Martinez FJ, Calverley PMA, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): A multicentre randomised controlled trial. Lancet 2015;385:857-866.
Braman SS. Hospital readmissions for COPD: we can meet the challenge. Chronic Obstr Pulm Dis 2015;2:4-7.
Mantero M, Rogliani P, Di Pasquale M, Polverino E, Crisafulli E, Guerrero M, et al. Acute exacerbations of COPD: Risk factors for failure and relapse. Int J Chron Obstruct Pulmon Dis 2017;12: 2687-2693.
Miravitlles M, Anzueto A. Antibiotics for acute and chronic respiratory infection in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188:1052-1057.
Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics-part 1: Biological mechanisms. Respiration 2011;81:67-74.
Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics-part 2: Advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration 2011;81:75-87.
Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-1121.
Lode H. The pharmacokinetics of azithromycin and their clinical significance. Eur J Clin Microbiol Infect Dis 1991;10: 807-812.
Brown BA, Griffith DE, Girard W, Levin J, Wallace RJ Jr. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clin Infect Dis 1997;24: 958-964.
Albert RK, Schuller JL; COPD Clinical Research Network. Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med 2014;189:1173-1180.
Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: A randomised, double-blind, placebo-controlled study. Lancet 2007; 369:482-490.
Wenzel RP, Fowler AA III, Edmond MB. Antibiotic prevention of acute exacerbations of COPD. N Engl J Med 2012;367: 340-347.
Desai H, Richter S, Doern G, Heilmann K, Dohrn C, Johnson A, et al. Antibiotic resistance in sputum isolates of Streptococcus pneumoniae in chronic obstructive pulmonary disease is related to antibiotic exposure. COPD 2010;7:337-344.
Lim E, Brown A, Helmy A, Mussa S, Altman DG. Composite outcomes in cardiovascular research: A survey of randomized trials. Ann Intern Med 2008;149:612-617.
Molyneaux PL, Mallia P, Cox MJ, Footitt J, Willis-Owen SA, Homola D, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188:1224-1231.
Lin C, Pang Q. Meta-analysis and systematic review of procalcitoninguided treatment in acute exacerbation of chronic obstructive pulmonary disease. Clin Respir J 2018;12:10-15.
Corti C, Fally M, Fabricius-Bjerre A, Mortensen K, Jensen BN, Andreassen HF, et al. Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. Int J Chron Obstruct Pulmon Dis 2016;11:1381-1389.
